Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Adaptimmune Therapeutics PLC (ADAP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K/A
| Financial Statements and Exhibits Interactive Data |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
SC 13G/A
| Matrix Capital Management Company, LP reports a 17.3% stake in Adaptimmune Therapeutics PLC |
| 06/29/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 06/29/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 06/29/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/01/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; Election of Directors; Appoin...|
Docs:
|
"CONFIDENTIAL",
"Letter of appointment The board of directors of Adaptimmune Therapeutics plc is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Remuneration Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be based in, and perform your role as a non-executive, independent director and as a member of the Board's Remuneration Committee from [*]. This letter sets out the main terms of your appointment. If you need any more information, please let me know. By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restrictions which prevent you from holding office as a d...",
"Letter of appointment The board of directors of Adaptimmune Therapeutics plc is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Corporate Governance and Nominating Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be based in, and perform your role as a non-executive, independent director and as a member of the Board's Corporate Governance and Nominating Committee from [*]. This letter sets out the main terms of your appointment. If you need any more information, please let me know. By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restriction...",
"Letter of appointment The board of directors of Adaptimmune Therapeutics plc is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Audit Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be based in, and perform your role as a non-executive, independent director and as a member of the Board's Audit Committee from [*]. This letter sets out the main terms of your appointment. If you need any more information, please let me know. By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restrictions which prevent you from holding office as a director. 1. AP...",
"Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023 Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelin Preclinical programs targeting PRAME and CD70 in IND-enabling studies Adaptimmune funded into early 2026 with multiple value creating catalysts Webcast to be held tomorrow, June 2nd at 8 a.m. EDT: https://www.gowebcasting.com/12589" |
|
| 05/30/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/12/2023 |
8-K
| Quarterly results |
| 04/21/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/20/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/18/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 04/05/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 04/03/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/09/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/09/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/06/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"Exhibit 2.1    EXECUTION VERSION   AGREEMENT AND PLAN OF MERGER   BY AND AmONG   Adaptimmune therapeutics plc,   cm Merger sub, Inc.   AND   tcr 2 therapeutics inc.",
"Agreement”) is made and entered into as of March 5, 2023 , by and among Adaptimmune Therapeutics PLC , a public company limited by shares incorporated in England and Wales, TCR 2 Therapeutics Inc. , a Delaware corporation and [STOCKHOLDER] . Each of Parent, the Company and the Stockholder are sometimes referred to as a “Party” and collectively as the “Parties",
"VOTING AND SUPPORT AGREEMENT   This Voting and Support Agreement is made and entered into as of March 5, 2023 , by and among  Adaptimmune Therapeutics PLC , a public company limited by shares incorporated in England and Wales,  TCR 2 Therapeutics Inc. , a Delaware corporation and  [SHAREHOLDER] . Each of Parent, the Company and the Shareholder are sometimes referred to as a “Party” and collectively as the “Parties”. Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Merger Agreement .   RECITALS   A.              Concurrently with the execution and delivery of this Agreement, Parent, the Company and CM Merger Sub, Inc...",
"Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors Compelling clinical data with clear paths to products and multiple near-term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST",
"of Section 27 A of the Securities Act of 1933",
"significant operational advantages",
"Email to Employees" |
|
| 02/14/2023 |
SC 13G/A
| PFM Health Sciences, LP reports a 3% stake in Adaptimmune Therapeutics PLC |
| 01/31/2023 |
8-K
| Termination of a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 01/18/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/02/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
8-K
| Quarterly results |
| 10/25/2022 |
8-K
| Quarterly results |
| 09/09/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|
|
|